A FRET-based high throughput screening assay to identify inhibitors of anthrax protective antigen binding to capillary morphogenesis gene 2 protein.
Anti-angiogenic therapies are effective for the treatment of cancer, a variety of ocular diseases, and have potential benefits in cardiovascular disease, arthritis, and psoriasis. We have previously shown that anthrax protective antigen (PA), a non-pathogenic component of anthrax toxin, is an inhibi...
Main Authors: | Michael S Rogers, Lorna M Cryan, Kaiane A Habeshian, Lauren Bazinet, Thomas P Caldwell, P Christine Ackroyd, Kenneth A Christensen |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3386954?pdf=render |
Similar Items
-
Binding of the von Willebrand Factor A Domain of Capillary Morphogenesis Protein 2 to Anthrax Protective Antigen Vaccine Reduces Immunogenicity in Mice
by: Fabiana Freire Mendes de Oliveira, et al.
Published: (2020-01-01) -
Optimization and validation of a DYRK1A TR-FRET assay for high-throughput screening
by: Michael Tarpley, et al.
Published: (2021-01-01) -
Perturbation of mouse retinal vascular morphogenesis by anthrax lethal toxin.
by: Jennifer L Bromberg-White, et al.
Published: (2009-09-01) -
Anthrax, Matrix Biology, and Angiogenesis: Capillary Morphogenesis Gene 2 Mediates Activity and Uptake of Type IV Collagen-Derived Anti-Angiogenic Peptides
by: Finnell, Jordan Grant
Published: (2017) -
Tumor endothelium marker-8 based decoys exhibit superiority over capillary morphogenesis protein-2 based decoys as anthrax toxin inhibitors.
by: Chenguang Cai, et al.
Published: (2011-01-01)